CME Information
Provider Statement: This continuing medical education activity is provided by 
.
Support Statement: This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Target Audience: The intended audience for this activity activities is oncologists and other health care professionals involved in the treatment of patients with melanoma.
Learning Objectives: Upon successful completion of this activity, participants should be better able to:
- Review the latest clinical evidence regarding the role of biomarkers, including BRAF and NRAS, in both prognosis and treatment for patients with advanced melanoma.
- Examine the latest clinical evidence regarding targeted therapies for the treatment of BRAF- or NRAS-positive metastatic melanoma.
Activity Chair:
Axel Hauschild, MD
Professor of Dermatology
Department of Dermatology, Campus Kiel
University Hospital
Kiel, Germany
Faculty:
Grant McArthur, MBBS, BMedSci, PhD, FRACP
Consultant Medical Oncologist
Director, Melanoma & Skin Service
Associate Director Cancer Research
Peter MacCallum Cancer Centre
Melbourne, Australia
Reviewers:
Jason Luke, MD
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP (Recertification review on 1/12/2018).
Accreditation:
Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material was originally approved for 1 year from the date of original release, January 26, 2017 to January 25, 2018. It has since been recertified for an additional year and will now expire on January 12, 2019.
How to Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, review the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 of the 3 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Activity Chair and Faculty member report the following relationships, which are accurate at the time of original content release (January 26, 2017):
Axel Hauschild, MD
Consulting Fee: Amgen, Bristol-Myers Squibb, MerckSerono, MSD, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche
Speakers Bureau: Amgen, Bristol-Myers Squibb, MerckSerono, MSD, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche
Contracted Research: Amgen, Bristol-Myers Squibb, MerckSerono, MSD, Novartis, Oncosec, Philogen, Pierre Fabre, Provectus, Regeneron, Roche
Grant McArthur, MBBS, BMedSci, PhD, FRACP
No relevant financial relationship to disclose.
Reviewers reports the following relationship(s):
Jason Luke, MD
Consulting Fee: Amgen, Array, EMD Serono
Contracted Research (paid to institution): AbbVie, BBI Therapeutics, Bristol-Myers Squibb, Celldex, Corvus Pharmaceuticals, Delcath, EMD Serono, Five Prime Therapeutics, Genentech, GlaxoSmithKline, Incyte, MedImmune, Merck, Novartis, Pharmacyclics
Ronald A. Codario, MD, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2017 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CME Questions?
Contact us at cme@vindicoCME.com